NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers

Conclusions The positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.

http://link.springer.com/10.1007/s00535-015-1078-8

Source: Journal of Gastroenterology - April 24, 2015 Category: Gastroenterology Source Type: research